Notwithstanding the success of the ToGA study, HER2 antibody-targeted therapy for gastric cancer has encountered numerous limitations over the past decade, failing to demonstrate the same dramatic efficacy seen in breast cancer. This evidence concerns the gene ERBB2 and gastric cancer.